文献速递胃肠外科

机器人辅助结直肠癌手术的肿瘤学与手术安全性:纵向前瞻性队列研究结果

The oncological and surgical safety of robot-assisted surgery in colorectal cancer: outcomes of a longitudinal prospective cohort study.
PubMed 文献 · Surg Endosc · 2019-01-28

该研究分析了378例I-III期结直肠癌患者的前瞻性队列数据,比较机器人辅助结直肠手术(RACRS)与腹腔镜结直肠手术(LCRS)。结果显示两组肿瘤学结局(切缘、淋巴结检出数、局部复发)无显著差异,RACRS组中转率和术中并发症率显著更低。结论认为RACRS在I-III期结直肠癌治疗中是安全的。

要点

  • RACRS与LCRS在结肠癌和直肠癌的肿瘤学结局(切缘、淋巴结数、局部复发)无显著差异。
  • RACRS组中转率(3% vs 9%, p=0.008)和术中并发症率(2% vs 8%, p=0.003)显著低于LCRS组。
  • 两组远处转移、生存率、手术时间、住院时间和严重术后并发症无显著差异。

核心结论

  • RACRS在I-III期结直肠癌治疗中是安全的,肿瘤学结局与LCRS无差异,且中转率和术中并发症率更低。

研究设计与样本

  • RACRS组206例(结肠129例,直肠77例),LCRS组172例(结肠138例,直肠34例)。
  • 主要结局为肿瘤学结局(根治性切缘、检出淋巴结数、局部复发),次要结局包括远处转移、总生存和无病生存、手术时间、中转、住院时间及并发症。

主要发现

  • 结肠癌:RACRS组与LCRS组根治性切缘率分别为99.3% vs 98.6%(p=0.60),平均检出淋巴结数16±6 vs 18±7(p=0.16),24个月局部复发率均为3.8%(p=0.99)。
  • 直肠癌:RACRS组与LCRS组根治性切缘率分别为89.6% vs 94.3%(p=0.42),平均检出淋巴结数16±8 vs 15±4(p=0.51),24个月局部复发率9.5% vs 5.6%(p=0.42)。
  • RACRS组中转率显著低于LCRS组(3% vs 9%,p=0.008),术中并发症率也显著更低(2% vs 8%,p=0.003)。
  • 两组远处转移发生率、生存率、手术时间、住院时间和严重术后并发症(Clavien-Dindo评分)无显著差异。

临床怎么用

  • 对于I-III期结直肠癌,RACRS可作为一种安全的手术选择,肿瘤学短期结局与LCRS相当。
  • RACRS可能降低中转开腹和术中并发症的风险,但需结合患者具体情况和医疗资源选择。

局限性

  • 中位随访时间仅15个月(范围0.2-36),长期肿瘤学结局需更长时间验证。
  • 非随机分组,可能存在选择偏倚。
  • 直肠癌亚组样本量较小(RACRS 77例 vs LCRS 34例),统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer is one of the most common cancers worldwide. Laparoscopic colorectal surgery (LCRS) is a frequently used modality. A new development in minimally invasive surgery is robot-assisted colorectal surgery (RACRS). METHODS: Prospectively collected data of 378 consecutive patients who underwent RACRS or LCRS for stage I-III colorectal cancer from Dec 2014 to Oct 2017 were analyzed. Primary outcome was oncological outcome (radical margins, number of retrieved lymph nodes, locoregional recurrence). Secondary outcomes were distant metastases, overall and disease-free survival, operation time, conversion, length of hospital stay, and intra- and post-operative complications. RESULTS: 206 RACRS (129 colon and 77 rectal) and 172 LCRS (138 colon and 34 rectal) procedures were included. Baseline characteristics were similar. Overall median follow-up time was 15 months (0.2-36). Oncological outcome was similar. In colon cancer, radical margins were achieved in 99.3% in RACRS group versus 98.6% in LCRS group (p = 0.60), the average number of harvested lymph nodes was 16 ± 6 versus 18 ± 7 (p = 0.16), and locoregional recurrence rate in 24 months was 3.8% vs 3.8% (p = 0.99), respectively. In rectal cancer, radical margins were achieved in 89.6% in RACRS group versus 94.3% in LCRS group (p = 0.42), the average number of harvested lymph nodes was 16 ± 8 versus 15 ± 4 (p = 0.51), and locoregional recurrence rate in 24 months was 9.5 versus 5.6% (p = 0.42), respectively. Incidence of metastasis, survival rates, operation time, length of hospital stay, and number of severe post-operative complications measured by Clavien-Dindo scores did not differ between RACRS and LCRS groups. Conversion and intra-operative complication rates were significantly lower in the RACRS group as compared to the LCRS group (3% vs 9%, p = 0.008 and 2% vs 8%, p = 0.003, respectively). CONCLUSION: RACRS is safe in the treatment of patients with stage I-III colorectal cancer. Oncological outcome did not differ between RACRS and LCRS groups. RACRS had lower conversion and intra-operative complication rates.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Polat F, Willems LH, Dogan K, et al. The oncological and surgical safety of robot-assisted surgery in colorectal cancer: outcomes of a longitudinal prospective cohort study. Surg Endosc. 2019. PMID: 30693389. doi:10.1007/s00464-018-06653-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。